Go to the list of all blogs
Anna G's Avatar
published in Blogs
Aug 04, 2023
TickeronGET DAILY SIGNALS
Inflammation Theme: Biotech & Pharma Sector Surges +9.15% in a Week - $CHRS $AMGN $PFE $JNJ $ATXS $RETA $ANAB $ZYME $ALLK

Inflammation Theme: Biotech & Pharma Sector Surges +9.15% in a Week - $CHRS $AMGN $PFE $JNJ $ATXS $RETA $ANAB $ZYME $ALLK

The inflammation theme is experiencing a remarkable surge in the biotech and pharmaceutical sector, with an impressive gain of +9.15% in just one week. This theme includes a diverse group of companies that are dedicated to the development of groundbreaking treatments for cancer, inflammation, and other diseases related to cell proliferation. Investors are closely watching the market movements in this category as it offers exciting opportunities for both short-term and long-term gains.

For those interested in the inflammation theme within the biotech and pharmaceutical sector, Tickeron's AI robot, "Swing Trader: Deep Trend Analysis v.2 (TA)," offers a remarkable annualized return of +67%. Don't miss the chance to explore potential swings in companies like AMGN, PFE, and JNJ with the AI-powered insights, increasing your chances of capitalizing on profitable opportunities within this theme.

Industry Description:
The inflammation theme focuses on biotech and pharmaceutical companies engaged in pioneering treatments for cancer, inflammation, and other diseases related to cell proliferation. These companies utilize cutting-edge technologies and research to develop therapies that address unmet medical needs. As leaders in the biotech and pharma sector, they contribute significantly to advancements in medical science and healthcare. Some of the notable companies operating in this field include Coherus BioSciences (CHRS), Amgen Inc. (AMGN), Pfizer Inc. (PFE), Johnson & Johnson (JNJ), Anteris Technologies Limited (ATXS), Reata Pharmaceuticals Inc. (RETA), AnaptysBio, Inc. (ANAB), Zymeworks Inc. (ZYME), and Allakos Inc. (ALLK).

Market Cap:

The average market capitalization across the inflammation theme is 64.5B. The market cap for tickers in this group ranges from 13.8M to an impressive 438.9B, with Johnson & Johnson (JNJ) holding the highest valuation at 438.9B and FWP being the lowest valued company at 13.8M.

High and Low Price Notable News:

Over the past week, the inflammation theme demonstrated robust performance, with an average weekly price growth of 7.27%. Notable price movements include a significant 56.95% price growth by RETA and a -4.19% decline in CHRS.

  • 7/22/23 6:50 AM: Johnson & Johnson (JNJ, $170.19) was a top weekly gainer, with a +6.46% jump.
  • 7/7/23 12:30 AM: Coherus BioSciences (CHRS, $4.64) was a top weekly gainer, with a +10.74% jump. Expect an Uptrend reversal.
  • 6/27/23 12:47 AM: Pfizer (PFE, $36.89) was a top loser this week, declining -7.91%.

Volume:
The average weekly volume growth across all stocks in the inflammation theme was -41.89%. While monthly volume growth recorded a slight increase of 0.22%, quarterly volume growth declined by -34.7%.

  • 8/1/23 1:27 AM: The volume for Reata Pharmaceuticals stock increased for one day, resulting in a record-breaking daily growth of 224% of the 65-Day Volume Moving Average.
  • 6/23/23 11:57 PM: The volume for Zymeworks stock increased for one day, resulting in a record-breaking daily growth of 1,128% of the 65-Day Volume Moving Average.
  • 6/23/23 11:57 PM: The volume for AnaptysBio stock increased for one day, resulting in a record-breaking daily growth of 281% of the 65-Day Volume Moving Average.

Fundamental Analysis Ratings:
The average fundamental analysis ratings for the inflammation theme, on a scale from 1 (best) to 100 (worst), are as follows:

  • Valuation Rating: 44
  • P/E Growth Rating: 84
  • Price Growth Rating: 55
  • SMR Rating: 74
  • Profit Risk Rating: 73
  • Seasonality Score: 22 (-100 ... +100)

Stock Analysis - Ticker Highlights:

JNJ: JNJ is in an upward trend, with the 10-day moving average crossing above the 50-day moving average on July 21, 2023. This signals a potential buy opportunity, as in 13 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.

Current price $169.99 crossed the support line at $169.60 and is trading between $185.96 resistance and $169.60 support lines. Throughout the month of 06/29/23 - 08/01/23, the price experienced a +3% Uptrend, while the week of 07/25/23 - 08/01/23 shows a -2% Downtrend.

ATXS: ATXS's MACD Histogram just turned positive on July 11, 2023. Looking at past instances where ATXS's MACD turned positive, the stock continued to rise in 38 of 44 cases over the following month. The odds of a continued upward trend are 86%.

Current price $8.95 is below $9.41, the lowest resistance line found by A.I. Throughout the month of 06/29/23 - 08/01/23, the price experienced a +7% Uptrend. During the week of 07/25/23 - 08/01/23, the stock enjoyed a +5% Uptrend growth.

RETA: RETA's Aroon Indicator triggered a bullish signal on August 02, 2023. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. In 191 of 222 similar instances, the stock moved higher in the days that followed. This puts the odds of a move higher at 86%.

Current price $166.51 is above $70.15, the highest support line found by A.I. Throughout the month of 06/29/23 - 08/01/23, the price experienced a +63%

Related Ticker: CHRS, AMGN, PFE, JNJ, ATXS, RETA, ANAB, ZYME, ALLK

CHRS sees MACD Histogram just turned negative

CHRS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 30, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 49 instances where the indicator turned negative. In 46 of the 49 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CHRS as a result. In 74 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for CHRS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +9.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where CHRS advanced for three days, in 182 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

CHRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.955) is normal, around the industry mean (3.596). P/E Ratio (-0.733) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.240) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (3.149) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. CHRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a maker of biologic therapeutics for oncology and inflammatory diseases

Industry Biotechnology

Industry
Biotechnology
Address
333 Twin Dolphin Drive
Phone
+1 650 649-3530
Employees
147
Web
https://www.coherus.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.